At its recent annual Science Day, Moderna signaled a profound strategic shift, moving beyond its foundational infectious disease vaccine and…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…
Read More
CEPI Fast-Tracks Three Ebola Vaccine Candidates from IAVI, Moderna, and Oxford Amidst Bundibugyo Outbreak in DRC and Uganda
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Moderna, the biotechnology firm that gained global prominence for its mRNA-based COVID-19 vaccine, is embarking on a significant strategic pivot,…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a critical initiative to accelerate the development of three investigational vaccines…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced a critical initiative to accelerate the development of three investigational vaccines…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna and Oxford
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and Oxford to Combat Bundibugyo Outbreak
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the urgent fast-tracking of three investigational vaccine candidates aimed at combating…
Read More
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
The U.S. Food and Drug Administration (FDA) has officially reversed its earlier decision regarding Moderna’s investigational mRNA influenza vaccine (mRNA-1010),…
Read More
FDA Rejects Moderna’s mRNA Flu Vaccine Application, Citing Comparator Study Flaws Amidst Broader Policy Shifts
Moderna, a leading biotechnology company, announced on Tuesday that the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation…
Read MoreYOU MAY HAVE MISSED
